Eli Lilly

Eli Lilly is not directly mentioned in the provided news articles. The articles primarily focus on Novo Nordisk, a Danish pharmaceutical company, and its weight-loss drug Wegovy (and Ozempic). Novo Nordisk is newsworthy due to the FDA approval of a pill form of Wegovy, marking a significant development in weight-loss medication. This approval is expected to increase competition and potentially lead to a rise in counterfeit weight-loss pills. Furthermore, Novo Nordisk anticipates a revenue drop in 2026 due to factors like potential price reductions influenced by political pressure, increased competition, and patent expirations. The articles also highlight concerns about the availability of prescription-only weight-loss injections without proper medical supervision and the potential for fake weight-loss treatments to enter the market, particularly with the introduction of easier-to-counterfeit pill forms.